Bexion Pharmaceuticals Inc. has selected Cytovance Biologics, Inc. to manufacture the protein component and active ingredient for Bexion’s first clinical compound, BXQ-350 to support Bexion’s drug development efforts, including planned Phase II trials. 
 
BXQ-350 is a formulation of the human lysosomal protein, Saposin C, and the phospholipid dioleoylphosphatidylserine (DOPS). The companies are working on the scale-up process in anticipation of increased drug requirements.

Bexion recently completed a Phase Ia dose ranging study in patients with advanced solid tumors, where BXQ-350 was shown to be well tolerated at all five doses with no dose limiting toxicities observed and no serious adverse events. Phase Ib is now underway.
 
“As Bexion’s need for BXQ-350 has continued to increase, Cytovance has been very responsive to our requests,” said Dr. Ray Takigiku, founder and chief executive officer of Bexion. “From scheduling multiple protein runs to improving our process, their team has provided welcomed expertise.”
 
“Cytovance is very excited to be a part of such an innovative project with Bexion,” said Mike O’Mara, vice president of manufacturing at Cytovance Biologics. “We are delighted to support Bexion by ongoing manufacturing of BXQ-350 in our cGMP state-of-the-art facilities.”